Bayer HealthCare Selects Tripos to Provide Drug Discovery Software For Its Global Enterprise

27-May-2004 - Germany

Tripos, Inc. and Bayer HealthCare AG have announced an agreement to deploy Tripos' proprietary discovery informatics software, SYBYL(R) and UNITY(R), globally across Bayer's drug discovery and development organization. Under the terms of the agreement, Tripos will provide Bayer with license rights to SYBYL and UNITY for its sites in Germany and the United States that are focused on the discovery and development of new therapeutics. Financial terms of the agreement were not disclosed.

The SYBYL computational chemistry and molecular modeling system is the heart of Tripos' discovery software offering, providing the fundamental components for research scientists to understand molecular structure and properties, with a special focus on the creation of new chemical entities. UNITY adds functionality to SYBYL with rapid, conformationally-flexible three-dimensional searching of chemical and biological databases.

"The seamless integration of cheminformatics, pharmacophore modeling and protein structure-based design tools offered by Tripos' software products will help us focus our synthesis efforts on promising compounds," said Dr. Hanno Wild, vice president for medicinal chemistry at Bayer HealthCare.

Dr. Alexander Hillisch, head of computational chemistry at Bayer HealthCare AG, added, "Tripos' ability to offer a complete computational chemistry suite, including sophisticated high-throughput docking programs on the Linux platform, was a critical factor in our choice."

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance